Hims & Hers Health Posts Weak Q2; Heading Into More Near-Term Challenges, Analysts Say
1. HIMS reported Q2 revenue of $544.8M, below the $551.7M estimate. 2. Analysts express concerns about core business growth and cash flow. 3. BofA maintains 'Underperform' rating; Needham reiterates 'Hold' rating. 4. Acquisition of ZAVA complicates regulatory landscape for HIMS. 5. Near-term performance tied to regulatory issues surrounding weight loss.